A Phase 1/2 Study of the Oral TRK Inhibitor LOXO101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

Trial Profile

A Phase 1/2 Study of the Oral TRK Inhibitor LOXO101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Larotrectinib (Primary) ; Larotrectinib (Primary)
  • Indications CNS cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SCOUT
  • Sponsors Loxo Oncology
  • Most Recent Events

    • 12 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 12 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
    • 06 Jun 2017 Results (data cut off: 31 Jan 2017, n=55) from NCT02122913, NCT02637687 and NCT02576431 studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top